Exagen (XGN)
(Real Time Quote from BATS)
$2.30 USD
+0.26 (12.75%)
Updated Aug 5, 2024 12:36 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Exagen Inc. (XGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.00 | $7.00 | $5.00 | 194.12% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Exagen Inc. comes to $6.00. The forecasts range from a low of $5.00 to a high of $7.00. The average price target represents an increase of 194.12% from the last closing price of $2.04.
Analyst Price Targets (4 )
Broker Rating
Exagen Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/14/2024 | William Blair | Andrew F Brackmann | Strong Buy | Strong Buy |
5/14/2024 | Cantor Fitzgerald & Co | Ross Osborn | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Daniel Brennan | Strong Buy | Strong Buy |
3/15/2024 | KeyBanc Capital Markets | Paul Knight | Hold | Hold |
1/7/2024 | BTIG | Mark Massaro | Strong Buy | Strong Buy |
10/23/2023 | Canaccord Genuity | Kyle Mikson | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $6.00 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 101 of 253 |
Current Quarter EPS Est: | -0.36 |